Key Insights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

1 of 0 completed with results

Key Signals

1 with results0

2Total

P 2 (1)

P 3 (1)

Terminated1

Recruiting1

Unknown1

Clinical Trials (3)

Showing 3 of 3 trials

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Prognostic Role of Platelet _lymphocyte and Neutrophil _monocyte in CLL

Showing all 3 trials